Thymic lymphomas in interleukin 9 transgenic mice. 1994

J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
Ludwig Institute for Cancer Research, Catholic University of Louvain, Brussels, Belgium.

Transgenic mice overexpressing the interleukin 9 gene were generated to study the biological activity of this cytokine in vivo. Although no major histological or morphological modifications of the lymphoid system were observed in most animals, approximately 7% of transgenic mice developed thymic lymphomas at the age of 3-9 months. The tumor cells, which were clonal, with unique T cell rearrangements, were double positive for the expression of CD4 and CD8. The need for additional transforming events, suggested by the low incidence of spontaneous tumors, was further indicated by the high susceptibility of the transgenic animals to injections of low doses of N-methyl-N-nitrosourea, a chemical carcinogen with a thymic tropism. Expression of interleukin 9 was required for optimal tumor growth in vivo, as one of the tumors studied, which had lost the transgene, was much more efficiently transplanted into transgenic than in normal mice. Moreover, the in vitro proliferative activity of interleukin 9 on cell lines derived from such transgene-negative tumors suggests that an autocrine loop mediates the proliferation of these cells in vivo. Taken together, these results indicate that dysregulated IL-9 expression could be involved in the development of some T cell malignancies.

UI MeSH Term Description Entries
D008770 Methylnitrosourea A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties. Nitrosomethylurea,N-Methyl-N-nitrosourea,NSC-23909,N Methyl N nitrosourea,NSC 23909,NSC23909
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013953 Thymus Neoplasms Tumors or cancer of the THYMUS GLAND. Cancer of Thymus,Thymus Cancer,Thymus Tumors,Cancer of the Thymus,Neoplasms, Thymic,Neoplasms, Thymus,Thymic Cancer,Thymic Neoplasms,Thymic Tumors,Cancer, Thymic,Cancer, Thymus,Cancers, Thymic,Cancers, Thymus,Neoplasm, Thymic,Neoplasm, Thymus,Thymic Cancers,Thymic Neoplasm,Thymic Tumor,Thymus Cancers,Thymus Neoplasm,Thymus Tumor,Tumor, Thymic,Tumor, Thymus,Tumors, Thymic,Tumors, Thymus
D016399 Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. T-Cell Lymphoma,Lymphoma, T Cell,Lymphomas, T-Cell,T Cell Lymphoma,T-Cell Lymphomas
D016906 Interleukin-9 A multifunctional cytokine secreted by primarily by activated TH2 CELLS that may play a role as a regulator of allergic INFLAMMATION. It has been shown to enhance the growth and CELL DIFFERENTIATION of MAST CELLS, and can act on a variety of other immune cells. IL-9,P40 T-Cell Growth Factor,T-Cell Growth Factor P40,IL9,Interleukin 9,P40 T Cell Growth Factor,T Cell Growth Factor P40
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
January 1997, International immunology,
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
February 1993, The Journal of experimental medicine,
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
January 1999, Postepy higieny i medycyny doswiadczalnej,
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
January 1993, Science (New York, N.Y.),
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
November 1997, Oncogene,
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
April 1981, Pathology, research and practice,
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
October 1996, Cellular immunology,
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
September 1994, Cancer research,
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
January 2003, Verhandlungen der Deutschen Gesellschaft fur Pathologie,
J C Renauld, and N van der Lugt, and A Vink, and M van Roon, and C Godfraind, and G Warnier, and H Merz, and A Feller, and A Berns, and J Van Snick
December 2014, Genes & development,
Copied contents to your clipboard!